92 related articles for article (PubMed ID: 24726873)
1. R-268712, an orally active transforming growth factor-β type I receptor inhibitor, prevents glomerular sclerosis in a Thy1 nephritis model.
Terashima H; Kato M; Ebisawa M; Kobayashi H; Suzuki K; Nezu Y; Sada T
Eur J Pharmacol; 2014 Jul; 734():60-6. PubMed ID: 24726873
[TBL] [Abstract][Full Text] [Related]
2. Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis.
Prakash J; de Borst MH; van Loenen-Weemaes AM; Lacombe M; Opdam F; van Goor H; Meijer DK; Moolenaar F; Poelstra K; Kok RJ
Pharm Res; 2008 Oct; 25(10):2427-39. PubMed ID: 18183478
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
Grygielko ET; Martin WM; Tweed C; Thornton P; Harling J; Brooks DP; Laping NJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):943-51. PubMed ID: 15769863
[TBL] [Abstract][Full Text] [Related]
4. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.
Fu K; Corbley MJ; Sun L; Friedman JE; Shan F; Papadatos JL; Costa D; Lutterodt F; Sweigard H; Bowes S; Choi M; Boriack-Sjodin PA; Arduini RM; Sun D; Newman MN; Zhang X; Mead JN; Chuaqui CE; Cheung HK; Zhang X; Cornebise M; Carter MB; Josiah S; Singh J; Lee WC; Gill A; Ling LE
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):665-71. PubMed ID: 18202322
[TBL] [Abstract][Full Text] [Related]
5. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
[TBL] [Abstract][Full Text] [Related]
6. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor.
Bonniaud P; Margetts PJ; Kolb M; Schroeder JA; Kapoun AM; Damm D; Murphy A; Chakravarty S; Dugar S; Higgins L; Protter AA; Gauldie J
Am J Respir Crit Care Med; 2005 Apr; 171(8):889-98. PubMed ID: 15563636
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
Sabat M; Wang H; Scorah N; Lawson JD; Atienza J; Kamran R; Hixon MS; Dougan DR
Bioorg Med Chem Lett; 2017 May; 27(9):1955-1961. PubMed ID: 28359790
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis.
de Gouville AC; Boullay V; Krysa G; Pilot J; Brusq JM; Loriolle F; Gauthier JM; Papworth SA; Laroze A; Gellibert F; Huet S
Br J Pharmacol; 2005 May; 145(2):166-77. PubMed ID: 15723089
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5).
Li X; Wang L; Long L; Xiao J; Hu Y; Li S
Bioorg Med Chem Lett; 2009 Aug; 19(16):4868-72. PubMed ID: 19616940
[TBL] [Abstract][Full Text] [Related]
11. ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles.
Řezníčková E; Tenora L; Pospíšilová P; Galeta J; Jorda R; Berka K; Majer P; Potáček M; Kryštof V
Eur J Med Chem; 2017 Feb; 127():632-642. PubMed ID: 28135685
[TBL] [Abstract][Full Text] [Related]
12. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ALK5 as a new approach to treat liver fibrotic diseases.
de Gouville AC; Huet S
Drug News Perspect; 2006 Mar; 19(2):85-90. PubMed ID: 16628263
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
Amada H; Sekiguchi Y; Ono N; Matsunaga Y; Koami T; Asanuma H; Shiozawa F; Endo M; Ikeda A; Aoki M; Fujimoto N; Wada R; Sato M
Bioorg Med Chem Lett; 2012 Mar; 22(5):2024-9. PubMed ID: 22325945
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK
Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.
Higashiyama H; Yoshimoto D; Kaise T; Matsubara S; Fujiwara M; Kikkawa H; Asano S; Kinoshita M
Exp Mol Pathol; 2007 Aug; 83(1):39-46. PubMed ID: 17274978
[TBL] [Abstract][Full Text] [Related]
17. A sensitive short-term evaluation of antifibrotic effects using newly established type I collagen reporter transgenic rats.
Terashima H; Kato M; Yasumo H; Tsuchida H; Mizuno M; Sada T
Am J Physiol Renal Physiol; 2010 Oct; 299(4):F792-801. PubMed ID: 20660018
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Mohan AV; Park CY; Son JY; Sheen YY; Kim DK
Bioorg Med Chem Lett; 2011 Oct; 21(20):6049-53. PubMed ID: 21911290
[TBL] [Abstract][Full Text] [Related]
19. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
DaCosta Byfield S; Major C; Laping NJ; Roberts AB
Mol Pharmacol; 2004 Mar; 65(3):744-52. PubMed ID: 14978253
[TBL] [Abstract][Full Text] [Related]
20. 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Park HJ; Park SJ; Sheen YY; Kim DK
Bioorg Med Chem; 2014 May; 22(9):2724-32. PubMed ID: 24704197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
